Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | APLNR | P35414 | 1/20 | 0.41 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.40 |
| ▸ | BAD | Q92934 | 1/20 | 0.40 |
| ▸ | CDK4 | P11802 | 1/20 | 0.39 |
| ▸ | CCND1 | P24385 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6397950 | 0.88 | ELANE (0.40) | ELANECDK4CCND1 | |
| SCHEMBL6393899 | 0.88 | MCL1 (0.40) | MAPTSMN1; SMN2BCL2L1MCL1BAD | |
| SCHEMBL6396585 | 0.83 | KMT2A (0.41) | MCL1CDK4CCND1 | |
| SCHEMBL6396542 | 0.82 | CDK4 (0.40) | MAPTSMN1; SMN2MCL1CDK4CCND1 | |
| SCHEMBL6396758 | 0.82 | L3MBTL1 (0.41) | MCL1CDK4CCND1 | |
| SCHEMBL6401232 | 0.82 | CDK4 (0.49) | MCL1BADCDK4CCND1 | |
| SCHEMBL6395342 | 0.81 | LMNA (0.46) | SMN1; SMN2MCL1CDK4CCND1 | |
| SCHEMBL6401223 | 0.81 | CDK4 (0.48) | MCL1CDK4CCND1 | |
| SCHEMBL6398150 | 0.79 | EPHX1 (0.42) | SMN1; SMN2 | |
| SCHEMBL6394349 | 0.77 | RAB9A (0.41) | BCL2L1MCL1BADCDK4CCND1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050054629-A1 | Compounds and methods of treating cell proliferative diseases | EXONHIT THERAPEUTICS SA (FR) | 2005-03-10 | — | — | US | claimed |
| US-20050054629-A1 | Compounds and methods of treating cell proliferative diseases | EXONHIT THERAPEUTICS SA (FR) | 2005-03-10 | — | — | US | disclosed |
| EP-1480966-A1 | COMPOUNDS AND METHODS OF TREATING CELL PROLIFERATIVE DISEASES | Exonhit Therapeutics S.A. (FR) | 2004-12-01 | — | — | EP | disclosed |
| WO-2003074508-A1 | COMPOUNDS AND METHODS OF TREATING CELL PROLIFERATIVE DISEASES | EXONHIT THERAPEUTICS SA (FR) | 2003-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054629-A1 | Compounds and methods of treating cell proliferative diseases | MKI67, CCNC, PCNA | ELANE 1534/4885MAPT 2267/4885SMN1; SMN2 1723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.